Spectral Med Stock Net Income
| EDT Stock | CAD 1.35 0.03 2.27% |
As of the 5th of February, Spectral Med has the Risk Adjusted Performance of (0.02), variance of 7.73, and Coefficient Of Variation of (2,739). Spectral Med technical analysis provides you with a way to harness past market data to determine a pattern that measures the direction of the company's future prices.
Spectral Med Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 146.6644 | Revenue | Earnings Share (0.14) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -13.9 M | -13.2 M | |
| Net Loss | -13.9 M | -14.5 M | |
| Net Loss | -13.9 M | -14.6 M | |
| Net Loss | (0.05) | (0.05) | |
| Net Income Per E B T | 1.15 | 1.34 |
Spectral | Net Income |
Evaluating Spectral Med's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Spectral Med's fundamental strength.
Latest Spectral Med's Net Income Growth Pattern
Below is the plot of the Net Income of Spectral Med over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Spectral Med financial statement analysis. It represents the amount of money remaining after all of Spectral Med operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Spectral Med's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spectral Med's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (15.39 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Spectral Net Income Regression Statistics
| Arithmetic Mean | (9,271,265) | |
| Coefficient Of Variation | (43.51) | |
| Mean Deviation | 3,106,603 | |
| Median | (9,492,000) | |
| Standard Deviation | 4,034,289 | |
| Sample Variance | 16.3T | |
| Range | 13.2M | |
| R-Value | (0.60) | |
| Mean Square Error | 11.1T | |
| R-Squared | 0.36 | |
| Significance | 0.01 | |
| Slope | (481,229) | |
| Total Sum of Squares | 260.4T |
Spectral Net Income History
Spectral Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Spectral Med is extremely important. It helps to project a fair market value of Spectral Stock properly, considering its historical fundamentals such as Net Income. Since Spectral Med's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Spectral Med's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Spectral Med's interrelated accounts and indicators.
Click cells to compare fundamentals
Spectral Med 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Spectral Med's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Spectral Med.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Spectral Med on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Spectral Med or generate 0.0% return on investment in Spectral Med over 90 days. Spectral Med is related to or competes with High Tide, Cipher Pharmaceuticals, Aurora Cannabis, Fennec Pharmaceuticals, Canopy Growth, Eupraxia Pharmaceuticals, and Kneat. Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America More
Spectral Med Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Spectral Med's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Spectral Med upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 15.23 | |||
| Value At Risk | (4.48) | |||
| Potential Upside | 4.44 |
Spectral Med Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Spectral Med's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Spectral Med's standard deviation. In reality, there are many statistical measures that can use Spectral Med historical prices to predict the future Spectral Med's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.32) | |||
| Treynor Ratio | 0.4475 |
Spectral Med February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 0.4575 | |||
| Mean Deviation | 2.02 | |||
| Coefficient Of Variation | (2,739) | |||
| Standard Deviation | 2.78 | |||
| Variance | 7.73 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.32) | |||
| Treynor Ratio | 0.4475 | |||
| Maximum Drawdown | 15.23 | |||
| Value At Risk | (4.48) | |||
| Potential Upside | 4.44 | |||
| Skewness | 0.6846 | |||
| Kurtosis | 1.7 |
Spectral Med Backtested Returns
Spectral Med owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0189, which indicates the firm had a -0.0189 % return per unit of risk over the last 3 months. Spectral Med exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Spectral Med's Coefficient Of Variation of (2,739), risk adjusted performance of (0.02), and Variance of 7.73 to confirm the risk estimate we provide. The entity has a beta of -0.25, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Spectral Med are expected to decrease at a much lower rate. During the bear market, Spectral Med is likely to outperform the market. At this point, Spectral Med has a negative expected return of -0.0542%. Please make sure to validate Spectral Med's daily balance of power, price action indicator, as well as the relationship between the potential upside and jensen alpha , to decide if Spectral Med performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.19 |
Insignificant reverse predictability
Spectral Med has insignificant reverse predictability. Overlapping area represents the amount of predictability between Spectral Med time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Spectral Med price movement. The serial correlation of -0.19 indicates that over 19.0% of current Spectral Med price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.19 | |
| Spearman Rank Test | 0.26 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Spectral Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Spectral Med reported net income of (15.39 Million). This is 104.51% lower than that of the Biotechnology sector and 108.89% lower than that of the Health Care industry. The net income for all Canada stocks is 102.7% higher than that of the company.
Spectral Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Spectral Med's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Spectral Med could also be used in its relative valuation, which is a method of valuing Spectral Med by comparing valuation metrics of similar companies.Spectral Med is currently under evaluation in net income category among its peers.
Spectral Med Current Valuation Drivers
We derive many important indicators used in calculating different scores of Spectral Med from analyzing Spectral Med's financial statements. These drivers represent accounts that assess Spectral Med's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Spectral Med's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 94.2M | 55.5M | 99.8M | 118.4M | 106.6M | 111.9M | |
| Enterprise Value | 89.0M | 47.2M | 99.0M | 124.0M | 111.6M | 117.2M |
Spectral Fundamentals
| Return On Equity | -9.74 | ||||
| Return On Asset | -0.87 | ||||
| Operating Margin | (4.13) % | ||||
| Current Valuation | 396.73 M | ||||
| Shares Outstanding | 289.14 M | ||||
| Shares Owned By Insiders | 17.88 % | ||||
| Shares Owned By Institutions | 12.56 % | ||||
| Number Of Shares Shorted | 394.17 K | ||||
| Price To Earning | (16.07) X | ||||
| Price To Book | 49.87 X | ||||
| Price To Sales | 144.30 X | ||||
| Revenue | 2.29 M | ||||
| Gross Profit | 1.69 M | ||||
| EBITDA | (11.97 M) | ||||
| Net Income | (15.39 M) | ||||
| Cash And Equivalents | 3.8 M | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 14.93 M | ||||
| Debt To Equity | 16.30 % | ||||
| Current Ratio | 6.95 X | ||||
| Book Value Per Share | (0.24) X | ||||
| Cash Flow From Operations | (8.82 M) | ||||
| Short Ratio | 6.20 X | ||||
| Earnings Per Share | (0.14) X | ||||
| Target Price | 3.1 | ||||
| Number Of Employees | 29 | ||||
| Beta | 0.27 | ||||
| Market Capitalization | 428.82 M | ||||
| Total Asset | 5.32 M | ||||
| Retained Earnings | (140.84 M) | ||||
| Working Capital | (22.99 M) | ||||
| Net Asset | 5.32 M |
About Spectral Med Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Spectral Med's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spectral Med using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spectral Med based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Spectral Med
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spectral Med position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spectral Med will appreciate offsetting losses from the drop in the long position's value.Moving against Spectral Stock
The ability to find closely correlated positions to Spectral Med could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spectral Med when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spectral Med - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spectral Med to buy it.
The correlation of Spectral Med is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spectral Med moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spectral Med moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spectral Med can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Spectral Stock
Spectral Med financial ratios help investors to determine whether Spectral Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spectral with respect to the benefits of owning Spectral Med security.